Work to help oral prostate cancer medications work better in the body has been making significant progress thanks to your donations!
Professor Clive Prestidge and team at the University of South Australia’s Centre for Pharmaceutical Innovation (CPI) have been developing new formulations for oral drugs like Zytiga (known clinically as Abiraterone Acetate).
Abiraterone Acetate is a widely-used treatment for men with prostate cancer that has spread to other parts of the body.
“Abiraterone Acetate helps to control testosterone levels and slow cancer progression,” Prof Prestidge said.
“It is available as an oral dose but can have erratic and low absorption into the blood stream, plus requires men to fast prior to and after taking four large tablets.”
Thanks to your support, Prof Prestidge and team have been able to develop a wide range of formulations which show promise in improving the effectiveness of the medication.
“Our optimal formulations significantly improve the solubility of Abiraterone Acetate in gastro-intestinal conditions and reduce the food-effect when tested in the lab,” he said.
“Further pre-clinical studies have also commenced and are confirming that our drug formulations have better absorption.
“Our next step is to improve dosing strategies. Our early findings are providing important insight into the potential of dose reduction, reduced food effects and will better enable the clinical translation of novel Abiraterone Acetate formulations.”
This two-year project is halfway through, so we look forward to keeping you updated!